The pharmacogenomics of Warfarin - Closing in on personalized medicine

被引：99

作者：

Rettie, Allan E. ^{[1
]}

Tai, Guoying ^{[1
]}

机构：

[1] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA

来源：

MOLECULAR INTERVENTIONS | 2006年 / 6卷 / 04期

关键词：

D O I：

10.1124/mi.6.4.8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Warfarin, a coumarin anticoagulant, is used worldwide for the treatment and prevention of thromboembolic disease. Warfarin therapy, however, can be difficult to manage because of the drug's narrow therapeutic index and the wide interindividual variability in patient response. It is now clear that genetic polymorphisms in genes influencing metabolism (CYP2C9) and pharmacodynamic response (VKORC1) are strongly associated with warfarin responsiveness. Optimal warfarin dosing in turn drives other positive anticoagulation-related outcomes. Therefore, a strong basic science argument is emerging for prospective genotyping of warfarin patients. Effective clinical translation would establish warfarin pharmacogenomics as a heuristic Model for personalized medicine.

引用

页码：223 / 227

页数：5

共 31 条

[1] Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity [J].

Bodin, L ;

Verstuyft, C ;

Tregouet, DA ;

Robert, A ;

Dubert, L ;

Funck-Brentano, C ;

Jaillon, P ;

Beaune, P ;

Laurent-Puig, P ;

Becquemont, L ;

Loriot, MA .

BLOOD, 2005, 106 (01) :135-140

[2] A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance [J].

Bodin, L ;

Horellou, MH ;

Flaujac, C ;

Loriot, MA ;

Samama, MM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (07) :1533-1535

[3] A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].

D'Andrea, G ;

D'Ambrosio, RL ;

Di Perna, P ;

Chetta, M ;

Santacroce, R ;

Brancaccio, V ;

Grandone, E ;

Margaglione, M .

BLOOD, 2005, 105 (02) :645-649

[4] Pharmacogenomics and individualized drug therapy [J].

Eichelbaum, M ;

Ingelman-Sundberg, M ;

Evans, WE .

ANNUAL REVIEW OF MEDICINE, 2006, 57 :119-137

[5]

FASCO MJ, 1982, J BIOL CHEM, V257, P4894

[6] Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans [J].

Guo, YJ ;

Zhang, YF ;

Wang, Y ;

Chen, XY ;

Si, DY ;

Zhong, DF ;

Fawcett, JP ;

Zhou, H .

DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) :749-753

[7] Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit I [J].

Harrington, DJ ;

Underwood, S ;

Morse, C ;

Shearer, MJ ;

Tuddenham, EGD ;

Mumford, AD .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) :23-26

[8] Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin [J].

Kidd, RS ;

Curry, TB ;

Gallagher, S ;

Edeki, T ;

Blaisdell, J ;

Goldstein, JA .

PHARMACOGENETICS, 2001, 11 (09) :803-808

[9]

Kresge N, 2005, J BIOL CHEM, V280

[10] The VKOR target for warfarin identified [J].

Le Bonniec, B .

M S-MEDECINE SCIENCES, 2004, 20 (05) :512-514

← 1 2 3 4 →